scholarly journals Low Molecular Weight Heparin Treatment Decreases MMP-9 Plasma Activity in Patients with Abdominal Aortic Aneurysm

2008 ◽  
Vol 35 (2) ◽  
pp. 159-161 ◽  
Author(s):  
T. Grzela ◽  
R. Brawura-Biskupski-Samaha ◽  
M.M. Jelenska ◽  
J. Szmidt
Keyword(s):  
Molecular Weight ◽  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Treatment ◽  
Abdominal Aortic ◽  
Plasma Activity

scholarly journals Metabolomic Profile of Abdominal Aortic Aneurysm

Metabolites ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 555
Author(s):  
Jüri Lieberg ◽  
Anders Wanhainen ◽  
Aigar Ottas ◽  
Mare Vähi ◽  
Mihkel Zilmer ◽  
...  
Keyword(s):  
Amino Acids ◽  
Molecular Weight ◽  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Slow Growth ◽  
Fast Growth ◽  
Low Molecular Weight ◽  
Targeted Analysis ◽  
Structural Deterioration ◽  
Abdominal Aortic

Abdominal aortic aneurysm (AAA) is characterized by structural deterioration of the aortic wall, leading to aortic dilation and rupture. The aim was to compare 183 low molecular weight metabolites in AAA patients and aorta-healthy controls and to explore if low molecular weight metabolites are linked to AAA growth. Blood samples were collected from male AAA patients with fast (mean 3.3 mm/year; range 1.3–9.4 mm/year; n = 39) and slow growth (0.2 mm/year; range −2.6–1.1 mm/year; n = 40), and from controls with non-aneurysmal aortas (n = 79). Targeted analysis of 183 metabolites in plasma was performed with AbsoluteIDQ p180 kit. The samples were measured on a QTRAP 4500 coupled to an Agilent 1260 series HPLC. The levels of only four amino acids (histidine, asparagine, leucine, isoleucine) and four phosphatidylcholines (PC.ae.C34.3, PC.aa.C34.2, PC.ae.C38.0, lysoPC.a.C18.2) were found to be significantly lower (p < 0.05) after adjustment for confounders among the AAA patients compared with the controls. There were no differences in the metabolites distinguishing the AAA patients with slow or fast growth from the controls, or distinguishing the patients with slow growth from those with fast growth. The current study describes novel significant alterations in amino acids and phosphatidylcholines metabolism associated with AAA occurrence, but no associations were found with AAA growth rate.

Markers of Hemostatic System Activation in Acute Deep Venous Thrombosis-Evolution during the First Days of Heparin Treatment

1993 ◽  
Vol 70 (06) ◽  
pp. 0909-0914 ◽  
Author(s):  
Keyword(s):  
Molecular Weight ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Unfractionated Heparin ◽  
Low Molecular Weight Heparin ◽  
Factor Xa ◽  
Low Molecular Weight ◽  
Dose Adaptation ◽  
Heparin Treatment ◽  
Lung Scan

SummaryFibrin D-Dimer (D-Di), prothrombin activation fragment (F 1+2) and thrombin-antithrombin III complexes (TAT) were measured using ELISA procedures in the plasma of patients with an acute deep venous thrombosis (DVT), at presentation and on days 2, 6 and 10 after initiation of heparin treatment. Patients were randomly allocated into two treatment groups: 44 patients received adapted doses of continuous intravenous unfractionated heparin (UH) whereas 47 received 1 mg/kg every twelve hours of a low molecular weight heparin (enoxaparin) subcutaneously. A phlebography and a perfusion lung scan were performed before inclusion and on day 10. Failure of therapy (n = 9) was defined by venogram worsening or confirmed pulmonary embolism. Improvement (n = 44) or stationary state (n = 38) were defined by venogram evolution in the absence of new leg scan defects.At presentation, D-Di, F 1 + 2 and TAT were above cut-off values in 97, 66 and 89% of patients respectively. D-Di levels correlated with the extent of venous thrombosis whereas TAT and F 1 + 2 did not. Mean levels of D-Di decreased sharply during the first days of treatment but were still abnormal on day 10. A secondary increase of D-Di on days 6 or 10 by more than 3 μg/ml occurred in 4 of the 9 patients who developed a thromboembolic recurrence but in none of the 72 patients who had a more favorable outcome. F 1 + 2 and TAT time-courses were not related to clinical evolution. In the Enoxaparin group, there was no relationship between antifactor Xa activities and any biological markers. TAT and F 1 + 2 levels fell on day 2 and remained stable until day 10. In contrast, in the UH group, TAT and F 1 + 2 did not significantly decrease on day 2, probably due to a delay in dose adaptation, but they declined slowly until day 10.In conclusion, D-Di displays a higher sensitivity than F 1 + 2 or TAT for the diagnosis of D\T. D-Di, but not TAT or F 1 + 2, follow-up seems to be of potential value for early detection of recurrency. Hemostatic activation is controlled earlier by fixed doses of a low molecular weight heparin, irrespective of the plasma anti-factor Xa activities, than by unfractionated heparin at adapted doses.

scholarly journals The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment

2020 ◽  
Vol Volume 11 ◽  
pp. 103-105 ◽  
Author(s):  
Alessandro Morotti ◽  
Enrica Branca ◽  
Angelo Guerrasio
Keyword(s):  
Molecular Weight ◽  
Hemorrhagic Shock ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Treatment

Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients

2015 ◽  
Author(s):  
Aurora Solier Lopez ◽  
Raquel Morillo Guerrero ◽  
Teresa Elías Hernández ◽  
Luis Jara Palomares ◽  
Remedios Otero Candelera
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Heparin Treatment
Sign in / Sign up

Export Citation Format

Share Document